First Wave BioPharma, Inc. announced the continued enhancement of the intellectual property portfolio governing niclosamide as a treatment for COVID-19-related gastrointestinal infections.
[First Wave BioPharma, Inc.]
Sorry, but the selected Zotpress account can't be found.